R&D Sponsored Webinar recap: The future of cell and gene therapy in rare d... For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of them
Sales & Marketing Sponsored 12 Questions with Kirsten Parr Kirsten Parr heads up CMC Connect, a division of IPG Health Medical Communications, and has over 25 years’ experience in the industry.
Sales & Marketing Sponsored 12 Questions with Michael Stevinson Michael Stevinson is Global Agency Head at Caudex, an IPG Health Medical Communications company.
Sales & Marketing Sponsored 12 Questions with Ariel Buda-Levin Ariel Buda-Levin, MSc, is President of Medical Communications across Area23 on Hudson, ProHealth, and Trio, as well as the Commercial Medical Communications Champion at IPG Health Network.
Sales & Marketing Partner Content WINNER: Complete HealthVizion is PMEA Support Agency of the ... Complete HealthVizion is delighted to be awarded PMEA’s Support Agency of the Year, in recognition of the outstanding work of our teams.
Oncology Sponsored Meeting MSL training needs in an evolving landscape As medical treatments become more complex, the role of the Medical Science Liaison (MSL) has never been more important.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.